Table 2.
Sensitivity and specificity analyses for Gleason score (3+3) upgrade
| Characteristics | No upgrade, n (%) | Upgraded, n (%) | P | Sensitivity (%) | Specificity (%) | Correctly classify (%) | ROC area |
|---|---|---|---|---|---|---|---|
| Core+ ≥2 | 0.002* | 59.6 | 57.8 | 59.1 | 0.59 | ||
| No | 63 (37.1) | 107 (62.9) | |||||
| Yes | 46 (22.5) | 158 (77.5) | |||||
| Maximum core+ length ≥2 mm | <0.001* | 67.6 | 56.0 | 64.1 | 0.62 | ||
| No | 61 (42.1) | 84 (57.9) | |||||
| Yes | 48 (21.5) | 175 (78.5) | |||||
| Percentage of tumor in maximum core+ ≥13% | <0.001* | 67.2 | 53.1 | 63.1 | 0.60 | ||
| No | 58 (40.0) | 87 (60.0) | |||||
| Yes | 51 (22.3) | 178 (77.7) | |||||
| Percentage of PCa in total specimen ≥4% | 0.006* | 57.9 | 57.8 | 57.9 | 0.58 | ||
| No | 63 (37.1) | 107 (62.9) | |||||
| Yes | 46 (23.8) | 147 (76.2) | |||||
| Age ≥60 years | 0.001* | 46.4 | 71.6 | 53.7 | 0.59 | ||
| No | 78 (35.5) | 142 (64.5) | |||||
| Yes | 31 (20.1) | 123 (79.9) | |||||
| PSA ≥4.3 ng ml−1 | <0.001* | 67.2 | 52.3 | 62.8 | 0.60 | ||
| No | 57 (39.6) | 87 (60.4) | |||||
| Yes | 52 (22.6) | 178 (77.4) | |||||
| PSAD ≥0.13 ng ml−1 | <0.001* | 62.4 | 63.8 | 62.8 | 0.63 | ||
| No | 60 (40.5) | 88 (59.5) | |||||
| Yes | 34 (18.9) | 146 (81.1) | |||||
| Total number of biopsy cores ≥12 | 0.095 | 62.5 | 28.4 | 52.6 | 0.45 | ||
| No | 31 (23.8) | 99 (76.2) | |||||
| Yes | 78 (32.1) | 165 (67.9) |
*P<0.05 was considered statistically significant. PCa: prostate cancer; PSA: prostate-specific antigen; PSAD: prostate-specific antigen density; ROC: receiver operating characteristic